REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to define the standard use of TCM treatment regimen as the TCM cohort group and the non-TCM cohort group of those who use conventional Western medicine treatment without the standard TCM treatment regimen through a multi-center, large-sample prospective cohort study design. To evaluate the clinical efficacy and safety of TCM treatment regimens in the treatment of bronchial asthma, and to provide high-quality evidence for the promotion and application of TCM syndrome differentiation treatment in bronchial asthma.

Clinical Trial Description

Bronchial asthma is characterized by chronic inflammation of the airways, which is often recurrent, long-lasting and difficult to cure. Clinical studies have confirmed that the clinical symptoms and quality of life of asthma patients have been significantly improved after TCM intervention. However, most of the current clinical research methods on asthma are small-sample and RCT studies, resulting in insufficient demonstration of efficacy, and there is an urgent need to carry out multi-center, large-sample, high-quality real-world studies in order to obtain higher quality evidence-based medical evidence. This is a multi-center, large-sample prospective cohort study, which will evaluate the clinical efficacy and safety of TCM treatment regimens in the treatment of bronchial asthma, and provide high-quality evidence for the promotion and application of TCM syndrome differentiation therapy in bronchial asthma. The cohort study will enroll 1508 patients, and the standard use of TCM treatment regimen will be set as the TCM cohort group, and those who will use the conventional treatment of Western medicine but not the standard TCM treatment regimen will be the non-TCM cohort group. The asthma control rate was the main outcome index, and the asthma control questionnaire (ACQ), asthma quality of life score (AQLQ), clinical symptom and sign score, lung function, exhaled nitric oxide, induced sputum inflammation phenotype, glucocorticoid dose, and fast-acting β2 agonist dose were the secondary outcome indicators. Follow-up was conducted every 3 months for 1 year. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06373692
Study type	Observational
Source	Henan University of Traditional Chinese Medicine
Contact	Hai-bin Yu, Ph.D
Phone	+86 13526671773
Email	wwz1231125@163.com
Status	Not yet recruiting
Phase
Start date	May 1, 2024
Completion date	December 30, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02934945` - Treatment Efficacy of Budesonide/Formoterol in Cough Variant Asthma and Typical Asthma Patients	Phase 4
Completed	`NCT02561351` - Correlation Between Fractional Exhaled Nitric Oxide (FeNO) Levels and Asthma Exacerbation	N/A
Recruiting	`NCT01759472` - Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test	N/A
Completed	`NCT01918293` - Self-Management Using Smartphone Application for Chronic Disease Care in Real siTuation (SMART-Asthma): Adult	N/A
Completed	`NCT01203904` - Pulmicort Turbuhaler 100/200 Specific Clinical Experience Investigation	N/A
Completed	`NCT01762917` - Influence of Bag Volume Variation on the Reproducibility of Inert Gas Rebreathing	N/A
Completed	`NCT00536731` - Symbicort Rapihaler Therapeutic Equivalence Study	Phase 3
Completed	`NCT00331929` - Respiratory Health Study of Children in Kiryat Tivon	N/A
Completed	`NCT00930826` - Childhood Asthma and Schooling: The Truth Unveiled	N/A
Completed	`NCT00327028` - Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma	Phase 4
Completed	`NCT00413387` - Efficacy and Tolerability of Beclomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI Via HFA-134a Vs. Budesonide 160 µg + Formoterol 4,5 µg Dry Powder Via Turbuhaler®. (Symbicort®)	Phase 3
Completed	`NCT00153283` - Study of Efficacy of Gabapentin in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT00950794` - Study of Salmeterol (SN408D) for Adult Asthma	Phase 4
Completed	`NCT00142025` - Study of Efficacy of Oxcarbazepine in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT00153270` - Study of Efficacy of Sodium Valproate in Therapy of Bronchial Asthma	Phase 4
Completed	`NCT03450434` - XC8 in the Treatment of Patients With Bronchial Asthma	Phase 2
Recruiting	`NCT05189613` - Mepolizumab Effectiveness in Severe Eosinophilic Asthma and Bronchiectasis	N/A
Recruiting	`NCT04128111` - Study on the Correlation Between TCM Syndrome, Inflammatory Phenotype and Biomarker of Bronchial Asthma
Completed	`NCT06326632` - Comparative Effectiveness Study of Constant-Load Versus Graded Aerobic Exercise in Obese Children With Bronchial Asthma	N/A
Completed	`NCT05088512` - The Role of Genetic Factors in the Development of Bronchial Asthma in the Kazakh Population

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms